Acurx Pharmaceuticals Closes $2.5 Million Registered Direct Offering
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has recently announced the successful closing of its registered direct offering, encompassing 2,463,058 shares of its common stock. These shares were priced at a market rate of $1.015 each under Nasdaq rules. This strategic move is part of Acurx's ongoing effort to secure resources for the development of its innovative antibiotics aimed at tackling difficult bacterial infections.
Purpose of the Offering
The capital raised from this offering, which totals approximately $2.5 million prior to any associated expenses and fees, will primarily be allocated towards working capital and general corporate objectives. This financial backing is crucial for Acurx as it pushes forward in its mission to develop a new class of antibiotics that can effectively target serious infections.
Details of the Offering
In conjunction with the public offering, Acurx engaged H.C. Wainwright & Co. as the exclusive placement agent. As part of the transaction, unregistered warrants to purchase the same number of common stock shares were also issued. These warrants are set with an exercise price of $0.90 and can be exercised upon issuance, providing additional financial flexibility for the company.
Regulatory Compliance
The common stock is being offered under a shelf registration statement that has been filed with the Securities and Exchange Commission. Acurx has ensured all regulatory requirements are met, illustrating its commitment to transparency and compliance in its financial operations. This offering was made solely by means of a prospectus complying with the regulations of the SEC.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that focuses on developing groundbreaking antibiotics for difficult-to-treat bacterial infections. Their innovative approach involves the creation of antibiotic candidates with a Gram-positive selective spectrum that inhibits bacterial DNA replication, which is key to stopping the spread of these challenging infections. The company is particularly known for its lead product candidate, ibezapolstat, which is set to enter Phase 3 clinical trials for treating Clostridioides difficile infections. In addition, Acurx is also working on other antibiotic candidates targeting serious pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).
Looking Ahead
Acurx is enthusiastic about its prospects as it plans to initiate international clinical trials shortly for ibezapolstat. The company is committed to leading the way in the fight against antibiotic-resistant infections, which is a growing concern in the healthcare community. In addition to advancing its flagship product, Acurx is also in the process of preclinical studies for other promising antibiotic agents that address unmet medical needs in bacterial resistance.
Frequently Asked Questions
What is Acurx Pharmaceuticals known for?
Acurx Pharmaceuticals specializes in developing a new class of antibiotics aimed at treating difficult bacterial infections, particularly Gram-positive bacteria.
How much has Acurx raised in the recent offering?
Acurx raised approximately $2.5 million through its recent direct registered offering.
What will the proceeds from the offering be used for?
The proceeds will be primarily used for working capital and other general corporate purposes to advance Acurx’s antibiotic development initiatives.
What is ibezapolstat?
Ibazapolstat is Acurx's lead antibiotic candidate designed to treat infections caused by Clostridioides difficile. It is set to enter Phase 3 clinical trials soon.
Who is the placement agent for the offering?
H.C. Wainwright & Co. served as the exclusive placement agent for this offering, helping facilitate the transaction smoothly.
